City of Miami Purchases AEDs for Police Vehicles Under Citywide PAD Program
11 Aprile 2005 - 8:30AM
PR Newswire (US)
City of Miami Purchases AEDs for Police Vehicles Under Citywide PAD
Program Purchase of Powerheart(R) AEDs for Public Access
Defibrillation Program Valued at Over $200,000 IRVINE, Calif.,
April 11 /PRNewswire-FirstCall/ -- Cardiac Science, Inc.
(NASDAQ:DFIB), a leading manufacturer of public-access
defibrillators (AEDs), today announced that the city of Miami
purchased approximately 100 new fully- automatic version
Powerheart(R) G-3 AEDs as part of its citywide Public Access
Defibrillation Program (PAD). The $200,000 order for Miami's "Team
for Life" PAD project follows the City's initial order last Fall
for 42 Powerhearts that were deployed in city buildings and parks.
The latest deployment of Powerhearts are earmarked principally for
use in city police vehicles. Miami's PAD project is an exclusive
public-private partnership between the city and Cardiac Science.
The goal of the project, which is being coordinated by the Miami
Department of Fire-Rescue, is to save lives and protect Miami
citizens and visitors by making AEDs more accessible in a variety
of settings throughout the city. The program includes comprehensive
AED/CPR training and AED program management services and a citywide
public awareness campaign on the importance of defibrillation
therapy and the use of AEDs to treat victims of a massive heart
attack, also called sudden cardiac arrest. The project began with
Miami's selection of Cardiac Science last fall as the city's
exclusive provider of AEDs. City officials stated that they plan to
deploy Powerheart AEDs in police and fire vehicles as well as city
facilities and other public locations where large numbers of people
congregate. "We are working very closely with city officials in
Miami to ensure their PAD program is as successful as the San Diego
Project Heartbeat PAD program where over 1,200 Powerheart AEDs have
been deployed since 2001 and dozens of lives have been saved as a
result," said Cardiac Science Chairman and Chief Executive Officer
Raymond W. Cohen. "We consider the partnership between Cardiac
Science and Miami to be an excellent example of how cities can work
with private industry to improve safety and public education.
Everyone who lives in Miami or visits the city could benefit
directly from the 'Team for Life' project." About Cardiac Science
Cardiac Science develops, manufactures and markets a complete line
of Powerheart(R) brand, automatic public access defibrillators
(AEDs), and offers comprehensive AED/CPR training and AED program
management services that facilitate successful deployments. The
company makes the Powerheart(R) CRM(R), the only FDA-cleared
therapeutic patient monitor that instantly and automatically treats
hospitalized cardiac patients who suffer life-threatening heart
rhythms. Cardiac Science also manufactures its AED products on a
private label basis for other leading medical companies such as
Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare.
For more information please visit http://www.cardiacscience.com/ or
call (949) 797-3800. This press release includes forward-looking
statements. These statements may be identified by the use of
forward-looking terminology such as "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may,"
"might," "plan," "potential," "predict," "should," or "will," or
the negative thereof or other variations thereon or comparable
terminology. Cardiac Science has based these forward-looking
statements on the current expectations, assumptions, estimates and
projections. While Cardiac Science believes the City of Miami PAD
project will lead to future purchases of AEDs and be a benefit to
the city of Miami and it citizens, these expectations, assumptions,
estimates and projections, while reasonable, are forward-looking
statements and are only predictions and involve known and unknown
risks and uncertainties, many of which are beyond our control.
Certain factors, including those discussed in Cardiac Sciences'
Annual Report on Form 10-K for the year ended December 31, 2004,
under the heading "Risk Factors," may cause the actual results,
performance or achievements to differ materially from any future
results, performance or achievements expressed or implied by these
forward-looking statements. Given these risks and uncertainties,
you are cautioned not to place undue reliance on such
forward-looking statements. We do not undertake any obligation to
update any such statements or to publicly announce the results of
any revisions to any such statements to reflect future events or
developments. Contact: Matt Clawson (Investors), or Michael
Gioffredi Len Hall (Media) Chief Marketing Officer Allen &
Caron Inc Cardiac Science, Inc. (949) 474-4300 (949) 797-3800
DATASOURCE: Cardiac Science, Inc. CONTACT: Matt Clawson
(Investors), , or Len Hall (Media), , both of Allen & Caron
Inc, +1-949-474-4300, for Cardiac Science, Inc.; or Michael
Gioffredi, Chief Marketing Officer of Cardiac Science, Inc.,
+1-949-797-3800, Web site: http://www.cardiacscience.com/
Copyright
Grafico Azioni Cardiac Science (NASDAQ:DFIB)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Cardiac Science (NASDAQ:DFIB)
Storico
Da Ott 2023 a Ott 2024